Bavarian ramps up mpox vaccine production

Bavarian Nordic shifts focus to increase mpox vaccine production, planning to deliver two million doses by year-end, with some orders moved from 2024 to 2025. After the WHO declared a global health crisis due to an outbreak in DR Congo, Bavarian Nordic announced a potential provision of 13 million doses by 2025 to meet medium-term demand. Additionally, they are assessing ways to expand capacity, considering production transfer to other companies globally. The first doses of their EMA-approved mpox vaccine arrived in DR Congo on September 5, with over 250,000 doses already sent, funded by the European Commission, the US, and Bavarian Nordic itself. Other countries have pledged another 500,000 doses. The vaccine, known as Jynneos, Imvamune, and Imvanex, is currently the only one approved for mpox by the EMA.